A phase I trial with extended cohort of gemcitabine and vinorelbine followed by autologous peripheral blood stem cell transplantation for recurrent or refractory Hodgkin’s lymphoma Alemtuzumab appears ...

Traditionally, vaccines have been utilized to generate immune responses to a pathogen in a naive population. In the setting of congenital cytomegalovirus (CMV) infection, a vaccine that, when ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of ...

This is a preview. Log in through your library . Abstract Sera were examined from 50 patients on the renal transplant unit, Cambridge, for antibody against cytomegalovirus by complement fixation and ...

T cells are adept at killing cytomegalovirus (CMV)-infected cells by virtue of a T cell receptor (TCR) that recognizes intracellular CMV-associated proteins that become presented on the cell surface.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of ...

A UCLA research team has found a new way to prompt the immune system to kill cells infected with cytomegalovirus (CMV), a life-threatening infection that is particularly deadly in immunocompromised ...

Antibodies that summon virus-engulfing white blood cells may play an important role in protecting infants from potentially serious congenital infection with human cytomegalovirus (HCMV), according to ...

A UCLA research team has found a new way to prompt the immune system to kill cells infected with cytomegalovirus (CMV), a life-threatening infection that is particularly deadly in immunocompromised ...

Phase 2 study to confirm dose to be initiated in near term, with planned interim analysis through 3 months; Phase 3 study planning is underway CMV is the most common infectious cause of birth defects ...